Biosimilars Can Help Cancer Patients

Thursday October 22, 2020

There are approximately 1.7 million new cases of cancer in the United States each year. Patients rely on FDA-approved medications to treat cancer and cancer-related symptoms. It is essential that patients can access these medicines through the pandemic and beyond. Generics and biosimilars can offer much-needed treatments with substantial cost savings.

Just as generics offer significant savings over brand-name medicines, biosimilars — FDA-approved alternatives to brand-name biologics — hold the promise of savings and access to cutting-edge biologic treatments. A recent ACS CAN report confirmed that patients and health care payers can save money when patients use a generic or biosimilar alternative to a branded drug. One breast cancer patient had nearly 30% savings by using a biosimilar instead of the brand-name biologic.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.